Diagnostic Imaging Medicare Benefits Schedule (MBS) item changes for 1 July 2022

This page provides information on the 1 July 2022 changes to MBS Diagnostic Imaging items

Page last updated: 04 April 2022

From 1 July 2022:

  • Two new MBS items will be introduced for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) study for the initial staging of intermediate to high-risk patients with prostate cancer and for the restaging of patients with recurrent prostate cancer.
  • Annual indexation of Magnetic Resonance Imaging (MRI) services will recommence and the MBS rebate for bulk billed MRI services will be brought in line with other diagnostic imaging services.

Changes to MBS Diagnostic Imaging items


Fact Sheet
PDF and Word versions
Factsheet - Medicare Benefits Schedule Items 61563 and 61564 – 1 July 2022
(Last updated:
18 March 2022)
PDF version - Medicare Benefits Schedule Items 61563 and 61564 – 1 July 2022 (PDF 205 KB)

Word version- Medicare Benefits Schedule Items 61563 and 61564 – 1 July 2022 (Word 97 KB)
Factsheet - Medicare Indexation of MRI and changes to the Bulking Billing Incentive for MRI – 1 July 2022
(Last updated:
18 March 2022)
PDF version - Medicare Indexation of MRI and changes to the Bulking Billing Incentive for MRI – 1 July 2022 (PDF 154 KB)

Word version - Medicare Indexation of MRI and changes to the Bulking Billing Incentive for MRI – 1 July 2022 (Word 90 KB)



In this section